Trial Profile
The efficacy of adalimumab and conventional antirheumatic drugs in alleviating axial and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Sulfasalazine
- Indications Spondylarthritis
- Focus Therapeutic Use
- Acronyms PETSPA
- 22 Feb 2017 Status changed from not yet recruiting to recruiting.
- 28 Jul 2015 New trial record